drugset / Trial / NCT00732511

Coreg CR, Blood Vessel Stiffness and Blood Vessel Function

NCT00732511

RandomizedParallel-groupOpen-label

Summary

We are comparing the blood pressure-lowering effects of two marketed medications, Coreg CR and Toprol XL. Although both drugs reduce blood pressure by blocking the action of noradrenaline on beta-receptors in the blood vessels, Coreg CR also blocks alpha-receptors, which may provide added blood pressure-lowering. In addition, Coreg CR may have anti-oxidant actions. Cells which line blood vessels (termed "endothelial cells") make nitric oxide (NO), which relaxes the muscle cells encircling the blood vessels, causing a reduction in blood pressure. When body cells use oxygen, they normally produce "free radicals", which can destroy NO,leading to high blood pressure, heart damage and worsenimg of diabetes. Antioxidants remove free radicals and prevent or repair this damage. In this study we will measure endothelial cell function, blood vessel wall stiffness, NO in exhaled breath, and blood levels of substances which reflect NO production and destruction to determine if a pure beta-blocker (Toprol XL) differs from an alpha/beta blocker (Coreg CR) in these effects. We will also examine the mechanism by which such differences might occur.

Timeline

Start
2008-04
Primary completion
2008-12
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Carvedilol Other / unclassified 20 mg
Subject Carvedilol Other / unclassified 40 mg
Subject Carvedilol Other / unclassified 80 mg
Comparator Metoprolol Other / unclassified 50 mg
Comparator Metoprolol Other / unclassified 100 mg
Comparator Metoprolol Other / unclassified 200 mg